SFX-01
Glioblastoma
Clinical (exact phase unspecified)Active (via collaboration)
Key Facts
Indication
Glioblastoma
Phase
Clinical (exact phase unspecified)
Status
Active (via collaboration)
Company
About TheraCryf
TheraCryf is a clinical-stage biotech developing innovative small molecule therapies for high-unmet-need brain disorders, with a strategy centered on proof-of-concept development followed by partnership with larger pharma. Its pipeline includes two advanced preclinical assets: a 'best-in-class' orexin-1 antagonist (Ox-1) for addictive behaviors and anxiety, and an atypical dopamine transporter inhibitor (DAT) for fatigue and narcolepsy. A third asset, SFX-01 (a stabilized sulforaphane), is being explored in glioblastoma via an external collaboration. The company is pre-revenue and aims to advance its lead program to clinic readiness by 2026.
View full company profileTherapeutic Areas
Other Glioblastoma Drugs
| Drug | Company | Phase |
|---|---|---|
| Ropidoxuridine (IPdR) | Shuttle Pharmaceuticals | Phase 2 |
| LNTH-2505 | Lantheus Medical Imaging | Preclinical |
| Leronlimab | CytoDyn | Preclinical |
| Glioblastoma Moonshot | Owkin | Research |
| OPC-001 (PDC Candidate) | Oncopeptides | Phase 1/Window-of-Opportunity |
| αvβ3-targeted ADC | Xintela | Preclinical |
| Undisclosed | Biossil | Phase 2/3 |
| GLIX1 | Hemispherian | Phase 1 |
| InC01 | InCephalo Therapeutics | Pre-clinical |
| Glioblastoma Combination Therapy | JLP Health | Pre-clinical |
| ENV105 | Kairos Pharma | IND Cleared |
| LMP744 | Gibson Oncology | Phase 2 |